Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Primary Care

Journal Scan / Research · September 15, 2016

Single-Inhaler Triple Therapy vs Inhaled Corticosteroid Plus Long-Acting β2-Agonist Therapy for COPD

The Lancet

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Single Inhaler Triple Therapy Versus Inhaled Corticosteroid Plus Long-Acting β2-Agonist Therapy for Chronic Obstructive Pulmonary Disease (TRILOGY): A Double-Blind, Parallel Group, Randomised Controlled Trial
Lancet 2016 Sep 03;388(10048)963-973, D Singh, A Papi, M Corradi, I Pavlišová, I Montagna, C Francisco, G Cohuet, S Vezzoli, M Scuri, J Vestbo

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading